- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03315507
A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH
October 7, 2019 updated by: PhaseBio Pharmaceuticals Inc.
An Open-Label, Dose Titration Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046, A Sustained-Release Analogue of Vasoactive Intestinal Peptide, In Adult Subjects With Pulmonary Arterial Hypertension
PB1046-PT-CL-0005 is an open-label, dose-titration study to assess the safety, tolerability, and hemodynamic effects of individually dose-titrated PB1046 administered by weekly subcutaneous injection for 8 weeks in adult subjects with PAH who have a permanently implanted hemodynamic monitor in the distal pulmonary artery.
The primary objectives of the study are to assess the overall safety, tolerability, and hemodynamic profile of a PB1046 across an individually titrated dose range.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
3
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- The Ohio State University Wexner Medical Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15212
- Allegheny General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Willing and able to provide written informed consent and follow all study-related procedures;
- Confirmed diagnosis of Pulmonary Arterial Hypertension (WHO Group 1) and WHO Functional Class II or III by clinical diagnostic criteria assessed by the Investigator and have a permanently implanted pulmonary artery hemodynamic monitor (IHM);
- Adult subjects ≥18 years of age willing and able to utilize contraception as needed for 30 days after their last dose of study drug;
- Body mass index ≥ 18 kg/m2 and ≤ 47 kg/m2;
- Receipt of Investigator-directed stable (no change in dose or addition or removal of a therapy) medical-therapy in accordance with local standard of care for the management of PAH for 30 days prior to screening and between screening and first dose and are in stable clinical condition;
- Screening hemoglobin ≥ 9.0 g/dL secondary to the volume of blood to be collected during the study period;
- Willing and able to return to the study unit for specified study visits, or accommodate home visits;
- Willing and able to transmit hemodynamics via IHM and monitor systemic blood pressure while at home and record results.
Exclusion Criteria:
- Concomitant medical disorder, condition, or history, that in the opinion of the Investigator would impair the subject's ability to participate in or complete the requirements of the study;
- Concomitant medical disorder that is expected to limit the subject's life-expectancy to ≤ 1 year;
- Pregnant or lactating female subjects;
- First positive result from serology testing at visit 1 (screening labs) for human immunodeficiency virus, hepatitis B surface antigen, or hepatitis C virus prior to first dose;
- Participation in another investigational study within 30 days prior to screening or are taking part in a non-medication study which, in the opinion of the Investigator, would interfere with the study compliance or outcome assessments;
- Use of bosentan therapy for PAH within 30 days prior to screening or during study participation;
- Sustained systolic blood pressure (SBP) < 95 mmHg and/or diastolic blood pressure (DBP) < 50 mmHg (confirmed by a duplicate seated reading) on at least 3 consecutive readings (self-monitored or office) prior to first dose, or overt symptomatic hypotension;
- Sustained resting heart rate >110 beats per minute (BPM) at screening (V1) or prior to first dose (confirmed by duplicate assessments of office vital signs or consecutive ECG assessments) on at least 3 consecutive readings prior to first dose;
- Clinically significant renal dysfunction as measured by the estimated glomerular filtration rate (eGFR) of < 40 mL/min/1.73m2 as calculated by the MDRD equation: eGFR = 175 x (Creat / 88.4)-1.154 x (Age)-0.203 x (0.742 if female) x (1.212 if African American) (conventional units);
- Clinically significant liver dysfunction as measured by any one of the following: a. alanine aminotransferase (ALT) >3.0 time ULN or; b. aspartate aminotransferase (AST) >3.0 time ULN or; c. serum bilirubin ≥ 1.6 mg/dL;
- Known history of substance abuse that in the opinion of the Investigator would impair the subject's ability to participate in or complete the requirements of the study;
- Any major surgical procedure within 30 days prior to screening or planned surgical procedure during the study period;
- In-patient hospitalization (defined as greater than 23 hours) within 30 days of subject dosing;
- Enrollment within the past 3 months prior to screening or plans to enroll during the study into a cardiopulmonary rehabilitation program;
- Other medical or psychiatric condition which, in the opinion of the Investigator, would place the subject at increased risk or would preclude obtaining voluntary consent or would confound the objectives of study;
- Known hypersensitivity to study drug or any of the excipients of the drug formulation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PB1046 Injection
PB1046 Subcutaneous Injection
|
Eight weekly doses of PB1046.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events
Time Frame: Pre-dose to 28 days after last dose
|
Incidence and severity of AEs (described descriptively) and their relationship to study drug
|
Pre-dose to 28 days after last dose
|
Vital Signs (Blood pressure)
Time Frame: Prior to eight weekly doses and 1 and 3 hours after the final dose and 1, 2, 3, 5, 7 and 28 days after final dose.
|
Changes from baseline in blood pressure and their relationship to study drug
|
Prior to eight weekly doses and 1 and 3 hours after the final dose and 1, 2, 3, 5, 7 and 28 days after final dose.
|
Vital Signs (Heart rate)
Time Frame: Prior to eight weekly doses and 1 and 3 hours after the final dose and 1, 2, 3, 5, 7 and 28 days after final dose.
|
Changes from baseline in heart rate and their relationship to study drug
|
Prior to eight weekly doses and 1 and 3 hours after the final dose and 1, 2, 3, 5, 7 and 28 days after final dose.
|
Laboratory Parameters (Lipids)
Time Frame: Pre-dose and 7 and 28 days after last dose
|
Changes from baseline in lipids and their relationship to study drug
|
Pre-dose and 7 and 28 days after last dose
|
Laboratory Parameters (Serum chemistry)
Time Frame: Pre-dose and prior to doses 2-8 and 7 and 28 days after last dose
|
Changes from baseline in serum chemistry and their relationship to study drug
|
Pre-dose and prior to doses 2-8 and 7 and 28 days after last dose
|
Laboratory Parameters (Urinalysis)
Time Frame: Pre-dose and prior to doses 2-8 and 7 and 28 days after last dose
|
Changes from baseline in urinalysis and their relationship to study drug
|
Pre-dose and prior to doses 2-8 and 7 and 28 days after last dose
|
Laboratory Parameters (NT-pro-BNP)
Time Frame: Prior to doses 1-8 and 7 and 28 days after last dose
|
Changes from baseline in NT-pro-BNP and their relationship to study drug
|
Prior to doses 1-8 and 7 and 28 days after last dose
|
Mean Pulmonary Artery Pressure
Time Frame: Prior to eight weekly doses and 1 and 3 hours after the final dose and 1, 2, 3, 5, 7, 8 and 28 days after final dose
|
Change from baseline in mean pulmonary artery pressure
|
Prior to eight weekly doses and 1 and 3 hours after the final dose and 1, 2, 3, 5, 7, 8 and 28 days after final dose
|
Cardiac Index
Time Frame: Prior to eight weekly doses and 1 and 3 hours after the final dose and 1, 2, 3, 5, 7, 8 and 28 days after final dose
|
Change from baseline in cardiac index
|
Prior to eight weekly doses and 1 and 3 hours after the final dose and 1, 2, 3, 5, 7, 8 and 28 days after final dose
|
Total pulmonary resistance
Time Frame: Prior to eight weekly doses and 1 and 3 hours after the final dose and 1, 2, 3, 5, 7, 8 and 28 days after final dose
|
Change from baseline in total pulmonary resistance
|
Prior to eight weekly doses and 1 and 3 hours after the final dose and 1, 2, 3, 5, 7, 8 and 28 days after final dose
|
Laboratory Parameters (Fasting Plasma Glucose)
Time Frame: Pre-dose and 7 and 28 days after last dose
|
Changes from baseline in fasting plasma glucose and their relationship to study drug
|
Pre-dose and 7 and 28 days after last dose
|
Laboratory Parameters (Hematology)
Time Frame: Pre-dose and prior to doses 2-8 and 7 and 28 days after last dose
|
Changes from baseline in hematology and their relationship to study drug
|
Pre-dose and prior to doses 2-8 and 7 and 28 days after last dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic Dose Exposures (AUC (0-t))
Time Frame: Prior to eight weekly doses and at 1, 3, 24, 48, 72,120, 168 and 192 hours after final dose.
|
Area under the curve over the dosing interval (AUC(0-t))
|
Prior to eight weekly doses and at 1, 3, 24, 48, 72,120, 168 and 192 hours after final dose.
|
Pharmacokinetic Dose Exposures (AUC (0-tmax))
Time Frame: Prior to eight weekly doses and at 1, 3, 24, 48, 72,120, 168 and 192 hours after final dose.
|
Area under the curve concentration-time profile (AUC(0-tmax))
|
Prior to eight weekly doses and at 1, 3, 24, 48, 72,120, 168 and 192 hours after final dose.
|
Pharmacokinetic Dose Exposures (Cmax)
Time Frame: Prior to eight weekly doses and at 1, 3, 24, 48, 72,120, 168 and 192 hours after final dose.
|
Maximum serum concentration (Cmax)
|
Prior to eight weekly doses and at 1, 3, 24, 48, 72,120, 168 and 192 hours after final dose.
|
Pharmacokinetic Dose Exposures (Tmax)
Time Frame: Prior to eight weekly doses and at 1, 3, 24, 48, 72,120, 168 and 192 hours after final dose.
|
Time to Cmax (Tmax)
|
Prior to eight weekly doses and at 1, 3, 24, 48, 72,120, 168 and 192 hours after final dose.
|
Pharmacokinetic Dose Exposures (Ctrough)
Time Frame: Prior to eight weekly doses and at 1, 3, 24, 48, 72,120, 168 and 192 hours after final dose.
|
Pre-dose serum concentrations at Weeks 1 through 7 and the concentrations after the last dose
|
Prior to eight weekly doses and at 1, 3, 24, 48, 72,120, 168 and 192 hours after final dose.
|
Pharmacokinetic Dose Exposures (t1/2)
Time Frame: Prior to eight weekly doses and at 1, 3, 24, 48, 72,120, 168 and 192 hours after final dose.
|
Half-life (t1/2)
|
Prior to eight weekly doses and at 1, 3, 24, 48, 72,120, 168 and 192 hours after final dose.
|
Pharmacokinetic Dose Exposures (Lambda z)
Time Frame: Prior to eight weekly doses and at 1, 3, 24, 48, 72,120, 168 and 192 hours after final dose.
|
Lambda z
|
Prior to eight weekly doses and at 1, 3, 24, 48, 72,120, 168 and 192 hours after final dose.
|
Pharmacokinetic Dose Exposures (Cl/F)
Time Frame: Prior to eight weekly doses and at 1, 3, 24, 48, 72,120, 168 and 192 hours after final dose.
|
Apparent clearance (Cl/F)
|
Prior to eight weekly doses and at 1, 3, 24, 48, 72,120, 168 and 192 hours after final dose.
|
Pharmacokinetic Dose Exposures (Vd/F)
Time Frame: Prior to eight weekly doses and at 1, 3, 24, 48, 72,120, 168 and 192 hours after final dose.
|
Volume of distribution (Vd/F)
|
Prior to eight weekly doses and at 1, 3, 24, 48, 72,120, 168 and 192 hours after final dose.
|
Immunogenicity
Time Frame: Prior to eight weekly doses and on study days 59, 77 and 105.
|
Incidence of immunogenicity
|
Prior to eight weekly doses and on study days 59, 77 and 105.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
6 Minute Walk Distance Test (6MWD)
Time Frame: Pre-dose and 7 days after final dose
|
Change from baseline in 6MWD
|
Pre-dose and 7 days after final dose
|
Borg Dyspnea Index (BDI)
Time Frame: Pre-dose and 7 days after final dose
|
Change from baseline in BDI
|
Pre-dose and 7 days after final dose
|
PAH Related Biomarkers
Time Frame: Prior to Dose 1, prior to Dose 5 and 7 days after final dose
|
Change from baseline in PAH related biomarkers
|
Prior to Dose 1, prior to Dose 5 and 7 days after final dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 20, 2017
Primary Completion (Actual)
August 8, 2019
Study Completion (Actual)
August 8, 2019
Study Registration Dates
First Submitted
October 2, 2017
First Submitted That Met QC Criteria
October 16, 2017
First Posted (Actual)
October 20, 2017
Study Record Updates
Last Update Posted (Actual)
October 8, 2019
Last Update Submitted That Met QC Criteria
October 7, 2019
Last Verified
October 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PB1046-PT-CL-0005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Arterial Hypertension
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
-
American Medical Association FoundationWithdrawnIdiopathic Pulmonary Arterial Hypertension.United States
-
Vanderbilt University Medical CenterRecruitingIdiopathic Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial Hypertension | Scleroderma Associated Pulmonary Arterial Hypertension | Appetite Suppressant Associate PAHUnited States
-
Gachon University Gil Medical CenterChonbuk National University Hospital; Samsung Medical Center; Pusan National... and other collaboratorsUnknownPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Deep Phenotyping | Heritable Pulmonary Arterial HypertensionKorea, Republic of
-
Amsterdam UMC, location VUmcZonMw: The Netherlands Organisation for Health Research and DevelopmentUnknown
-
Zhejiang UniversityUnknownIdiopathic Pulmonary Arterial HypertensionChina
-
Association de Recherche en Physiopathologie RespiratoireGlaxoSmithKline; Soladis; InterlisUnknownPulmonary Arterial Hypertension (PAH)France
-
Medical University of GrazLudwig Boltzmann Institute for Lung Vascular ResearchCompletedIdiopathic Pulmonary Arterial HypertensionAustria
-
Zhejiang UniversityCompletedIdiopathic Pulmonary Arterial HypertensionChina
-
Regina Steringer-MascherbauerUnknownPulmonary Arterial Hypertension WHO Group IAustria
Clinical Trials on PB1046 Subcutaneous Injection
-
PhaseBio Pharmaceuticals Inc.Completed
-
PhaseBio Pharmaceuticals Inc.TerminatedPulmonary Arterial HypertensionUnited States
-
Novartis PharmaceuticalsCompletedTreatment-Resistant DepressionSpain, Japan, Poland, United States
-
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Not yet recruiting
-
Ångstrom PharmaceuticalsCompletedOvarian Cancer | Primary Peritoneal CarcinomaUnited States
-
Staidson (Beijing) Biopharmaceuticals Co., LtdCompletedAntineutrophil Cytoplasmic Antibody Associated VasculitisUnited States
-
AstraZenecaParexelCompleted
-
Aerpio TherapeuticsCompleted
-
AstraZenecaCompletedHealthy Elderly | Mild-Moderate Alzheimer's DiseaseUnited States